Cardiac Biomarkers Market - Global Outlook & Forecast 2023-2028

Cardiac Biomarkers Market - Global Outlook & Forecast 2023-2028

The global cardiac biomarkers market is expected to grow at a CAGR of 12.14% from 2022-2028.

MARKET TRENDS & DRIVERS

Integration of Multiple Cardiac Biomarkers

Healthcare professionals increasingly recognize the value of combining information from various biomarkers to comprehensively understand a patient's cardiac health. This approach allows for more accurate risk assessment, early detection of cardiovascular diseases, and personalized treatment strategies. By analyzing multiple biomarkers simultaneously, clinicians can provide more tailored care and improve patient outcomes in a field where precision and timely intervention are crucial.

Increasing R&D Activities of Novel Cardiac Biomarkers

The cardiac biomarkers market is witnessing a significant trend of increasing research and development (R&D) activities focused on novel cardiac biomarkers. Researchers and companies are exploring innovative molecular indicators to enhance diagnostic accuracy, risk assessment, and personalized treatment strategies for cardiovascular diseases. This trend reflects a growing commitment to advancing cardiac diagnostics, leading to the discovery of new biomarkers that can provide deeper insights into heart health, enabling early detection and improved patient outcomes.

Growing Prevalence of Cardiovascular Diseases

The escalating prevalence of CVDs is a significant driving force for the cardiac biomarkers market. With CVDs becoming a leading cause of global mortality, there's a heightened need for accurate and timely diagnosis. Cardiac biomarkers offer critical insights into heart health, enabling early detection, precise risk assessment, and effective monitoring. As the burden of CVDs continues to rise, the demand for biomarker-based diagnostic tools is growing, facilitating proactive healthcare interventions and ultimately contributing to improved patient outcomes.

Increasing Demand for Point-of-care Cardiac Diagnostics

The cardiac biomarkers market is witnessing a surge in demand due to the increasing recognition of the value of point-of-care cardiac diagnostics. Healthcare providers are embracing rapid and convenient testing methods that offer real-time cardiac insights at the patient's bedside or in emergency settings. This trend is driven by the need for timely diagnosis and treatment of cardiovascular diseases, enhancing patient outcomes. The convenience and speed of point-of-care testing are reshaping the market, allowing for quicker interventions, risk assessment, and treatment monitoring, ultimately improving heart health management on a global scale.

SEGMENTATION INSIGHTS

INSIGHTS BY BY BIOMARKERS TYPE

The global cardiac biomarkers market by biomarkers type can be classified as troponin, creatine kinase (CK-MB), myoglobin, and others. The troponin segment accounted for the most significant industry share in 2022. Troponins are a group of cardiac biomarkers that have revolutionized diagnosing and managing CVDs. They are specific proteins found in cardiac muscle cells and are released into the bloodstream when there is damage to the heart muscle. Troponin biomarkers are pivotal in identifying cardiac conditions, assessing the severity of cardiac events, guiding treatment decisions, and predicting patient outcomes. Further, high-sensitivity troponin assays enhance this early detection capability, identifying tiny amounts of troponin in the blood, even without clinical symptoms.

Segmentation by Biomarkers Type

• Troponin
• Creatine Kinase (CK-MB)
• Myoglobin
• Other

INSIGHTS BY APPLICATION

The acute coronary syndrome (ACS) application segment accounted for the most significant global cardiac biomarkers market share in 2022. Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions caused by a sudden reduction or cessation of blood flow to the heart muscle due to atherosclerotic plaque rupture or erosion. Timely and accurate diagnosis of ACS is critical for guiding appropriate management and reducing morbidity and mortality. Cardiac biomarkers play a pivotal role in the assessment of ACS, aiding in the identification, risk stratification, and treatment of patients with this life-threatening condition. Cardiac biomarkers not only assistance in diagnosing ACS and risk stratification but also play a role in guiding treatment decisions. Elevated cardiac biomarkers indicate myocardial injury, emphasizing the need for immediate antiplatelet therapy, such as aspirin or P2Y12 inhibitors, to prevent further clot formation.

Segmentation by Application

• Acute Coronary Syndrome
• Myocardial Infraction
• Congestive Heart Failure
• Others

INSIGHTS BY END-USER

The global cardiac biomarkers market by end-user is segmented into hospitals, diagnostic laboratories, and others. In 2022, hospitals accounted for a significant share of the end-user segment. Hospitals serve as vital end-users of cardiac biomarkers, utilizing them in various aspects of patient care related to cardiovascular diseases. From the emergency department to inpatient settings, cardiac biomarkers are pivotal in diagnosing acute cardiovascular events, risk-stratifying patients, and guiding treatment decisions. These biomarkers' availability and accurate interpretation enable healthcare professionals to provide timely interventions and improve patient outcomes. By leveraging the power of cardiac biomarkers, hospitals can continue to make significant strides in improving the care and outcomes of patients with cardiovascular conditions.

Segmentation by End-user

• Hospitals
• Diagnostic Laboratories
• Other

GEOGRAPHICAL ANALYSIS

North America held the most prominent global cardiac biomarkers market share in 2022. The region's leadership is attributed to factors such as the high prevalence of CVDs, a well-established healthcare infrastructure, and robust research and development activities. The U.S. and Canada are the primary contributors to the market's growth in this region, with a focus on introducing innovative biomarkers and diagnostic technologies. Moreover, increasing awareness about early disease detection and prevention drives the adoption of cardiac biomarkers in clinical practice.

Segmentation by Geography

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• The U.K.
• Italy
• Spain
• APAC
• Japan
• China
• India
• South Korea
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• Turkey
• South Africa
• Saudi Arabia

VENDOR LANDSCAPE

The field of cardiac biomarkers has experienced significant growth and innovation over the past few decades, playing a pivotal role in diagnosing, prognosis, and managing CVDs. As one of the most critical segments within the broader healthcare industry, the global cardiac biomarkers market has become a competition hub, driven by the increasing prevalence of CVDs, advancements in diagnostic technologies, and the pursuit of improved patient outcomes. Furthermore, the cardiac biomarkers market is characterized by various players, including pharmaceutical companies, diagnostic manufacturers, biotechnology firms, and research institutions.

Key Company Profiles

• Abbott
• Bio-Rad Laboratories
• Danaher
• F.Hoffmann-La Roche
• PerkinElmer
• Siemens Healthineers

Other Prominent Vendors

• Abcam
• bioMérieux
• BioSupply
• BTNX
• CardioGenics
• Creative Diagnostics
• DiaSorin
• Life Diagnostics
• LumiraDx
• Medix Biochemica
• MESO SCALE DIAGNOSTICS
• MP Biomedicals
• Quidel
• Randox Laboratories
• Response Biomedical
• Tosoh

KEY QUESTIONS ANSWERED:

1. How big is the global cardiac biomarkers market?

2. What is the projected growth rate of the global cardiac biomarkers market?

3. What are the rising trends in the cardiac biomarkers market?

4. Which region holds the most significant global cardiac biomarkers market share?

5. Who are the key players in the global cardiac biomarkers market?